Tumor draining lymph nodes (tdLNs) were the location where dendritic cells primarily present antigens and T cells priming and proliferating.31,32 Therefore, tdLNs are the direct target of anti-PD-(L)1 and have been shown to play a key role in immunotherapy,33–35 although the response evaluation criteria of immunotherapy commonly used are still focused on the change of primary lesions and reported only tpCR and bpCR. The gene discussed is CD274; the disease is neoplasm.